Brief: SynAct Pharma To Acquire TXP Pharma For SEK 136 Mln
Dec 12 (Reuters) - SynAct Pharma AB SYNACT.ST :
* SYNACT PHARMA TO MAKE STRATEGIC ACQUISITION OF SWISS
BIOTECH
COMPANY TXP PHARMA
* HAS ENTERED INTO A CONDITIONAL AGREEMENT ON ACQUISITION OF
TXP
PHARMA AG
* PURCHASE PRICE CONSISTS OF A FIXED PURCHASE PRICE OF SEK
136
MILLION
* OPTION FOR POTENTIAL ADDITIONAL PURCHASE PRICE OF SEK 55
MILLION
Source text for Eikon: ID:nMFN65HrF1
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development